Skip to main content

Table 4 Baseline charateristics in NSCLC (N = 131)

From: The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

 Total (%)No Antibiotics (%)Antibiotics (%)p value
Age
 < 6556 (42.7)28 (39.4)28 (46.7)0.405
 ≥ 6575 (57.3)43 (60.6)32 (53.3) 
Sex
 Male99 (75.6)54 (76.1)45 (75)0.889
 Female32 (24.4)17 (23.9)15 (25) 
ECOG
 0–1116 (89.9)66 (95.7)50 (83.3)0.02
 2–313 (10.1)3 (4.3)10 (16.7) 
 Unkown220 
Stage
 III4 (3.1)3 (4.2)1 (1.7)0.625
 IV127 (96.9)68 (95.8)59 (98.3) 
Number of metastatic organ
 0 or 185 (64.9)47 (66.2)38 (63.3)0.732
 ≥ 246 (35.1)24 (33.8)22 (36.7) 
Brain metastasis
 No106 (80.9)57 (80.3)49 (81.7)0.841
 Yes25 (19.1)14 (19.7)11 (18.3) 
Number of treatment line
 1st39 (29.8)25 (35.2)14 (23.3)0.304
 2nd56 (42.7)29 (40.8)27 (45) 
 ≥ 3rd36 (27.5)17 (23.9)19 (31.7) 
ICI
 Nivolumab71 (54.2)44 (62)27 (45)0.024
 Pembrolizumab41 (31.3)15 (21.1)26 (43.3) 
Othersa19 (14.5)12 (16.9)7 (11.7) 
Treatment combination
 ICI alone104 (79.4)53 (74.6)51 (85)0.117
 ICI with ICI7 (5.3)3 (4.2)4 (6.7) 
 ICI with chemotherapy20 (15.3)15 (21.1)5 (8.3) 
Clinical trial
 Yes65 (49.6)46 (64.8)19 (31.7)< 0.001
 No66 (50.4)25 (35.2)41 (68.3) 
Hisotologic subtype
 Adenocarcinoma83 (63.4)46 (64.8)37 (61.7) 
 Squamous cell carcinoma44 (33.6)24 (33.8)20 (33.3) 
 Othersb4 (3.1)1 (1.4)3 (5) 
PD-L1
 Negative14 (13.6)11 (20.4)3 (6.1)0.058
 Low30 (29.1)17 (31.5)13 (26.5) 
 High59 (57.3)26 (48.1)33 (67.3) 
 Unkown281711 
EGFR
 Negative92 (88.5)53 (89.8)39 (86.7)0.617
 Positive12 (11.5)6 (10.2)6 (13.3) 
 Unkown271215 
Antibiotics type
 No Antibiotics71 (54.2)   
 Antibiotics60 (45.8)Cephalosporins17 (28.3) 
Fluoroquinolones16 (26.7) 
Beta-lactam/Betalactamase inhibitors9 (15) 
Othersc18 (30) 
Administration Route
 Oral37 37 (61.7) 
 Intravenous23 23 (38.3) 
  1. aAvelumab, N = 6; Durvalumab, N = 5; Ipilimumab, N = 8
  2. bSarcomatoid carcinoma, N = 2, Large cell neuroendocrine carcinoma, N = 1; Poorly differentiated carcinoma, N = 1
  3. cCarbapenem, Glycopeptides, Macrolides and etc.